Register for our free email digests:
Andrew McConaghie
Senior Writer
Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Latest From Andrew McConaghie
COVID-19 Vaccine Gives Moderna $18bn Launchpad Into HIV Vaccine, Cancer Therapies
A rush of additional orders from countries around the world has boosted the company’s prospects, and fueled its ambitions beyond COVID-19.
CEOs Face Grilling On Vaccine Supply In EU
AstraZeneca's CEO and other leaders from COVID-19 vaccine companies will face some tough questions in Brussels, but the European Commission wants to put differences behind it and solve the vaccine supply problem as soon as possible.
Real-World Data Confirm Pfizer and AZ COVID-19 Vaccine Efficacy – And Bolster UK Dosing Policy
Observational studies from the National Health Service show encouraging signs for the UK’s vaccination program.
Lilly Broadens Its CNS Reach With Rigel RIPK1 Deal
The RIPK1 inhibitor class has yet to reach proof-of-concept, but could bolster Lilly’s dogged pursuit of progress in Alzheimer’s disease.
Stung By COVID Critics, EU Looks To BARDA-Style Agency To Act Faster On Variants
The European Commission wants to learn from mistakes made in the COVID-19 crisis and to create an end-to-end system to co-ordinate funding, clinical research and manufacturing of vaccines.
Pfizer And Moderna Reap Rewards Of Expanded US And EU Deals
The two rival mRNA vaccines are proving attractive in the face of new variants, and could dominate once SARS-CoV2 enters the ‘endemic’ stage.